Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Two months isoniazid, rifampin and pirazinamid for latent tuberculosis infection Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Resistance to pyrazinamide of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 413s Year: 2007
Efficacy of intravenous isoniazid, rifampin and ethambutol administration in patients with failed treatment of tuberculosis and malabsorption syndrome Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Prevalence of cross-resistance between rifampicin and rifabutin in Mycobacterium tuberculosis isolates in a tertiary care hospital in India Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Rapid oral desensitisation to ethambutol, rifampicin and isoniazid Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009
High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Moxifloxacin, as an alternative in the treatment of patients with the newly diagnosed pulmonary TB with monoresistance to pirazinamid, or its intolerance Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Monoresistance to rifampicin – a problem for treatment results? Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
Is pyrazinamide really hepatotoxic? A study of tuberculous patients with hepatotoxicity in Bahawal Victoria hospital, Bahawalpur Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Comparison of genotype MTBDRplus assay for rapid detection of rifampicin and isoniazid resistance with conventional drug susceptibility tests in a tertiary care hospital in India Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR Year: 2016